IPP Bureau
Boehringer Ingelheim inaugurates largest European development centre for biotechnology
By IPP Bureau - April 25, 2023
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Serum & Biocon Biologics agree to restructure equity investment
By IPP Bureau - April 25, 2023
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India
By IPP Bureau - April 25, 2023
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Zydus receives final approval from the USFDA for Metronidazole Topical Cream
By IPP Bureau - April 25, 2023
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Indica Labs and Lunit enters into alliance for digital pathology AI workflows
By IPP Bureau - April 25, 2023
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Huge milestones made towards Zero Malaria goal, says GlobalData
By IPP Bureau - April 25, 2023
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Apollo launches Genomics Institute in Chennai
By IPP Bureau - April 25, 2023
Apollo continues to invest in genomics technology and research for better patient care
Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules
By IPP Bureau - April 24, 2023
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility
By IPP Bureau - April 24, 2023
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013
By IPP Bureau - April 24, 2023
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Aurisco expands Oligonucleotide capacity
By IPP Bureau - April 24, 2023
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Tissue engineered skin substitutes market to reach $3 billion by 2033, forecasts GlobalData
By IPP Bureau - April 24, 2023
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Cadila plans an injectable manufacturing facility in collaboration with Russia
By IPP Bureau - April 22, 2023
The interaction with key Government Officials and industry leaders led to a joint exploration of possible collaboration and investments in the Healthcare ecosystem between the two countries
LTS acquires Sorrel wearable injection device business
By IPP Bureau - April 22, 2023
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
Sai Life Sciences opens research facility SSRL
By IPP Bureau - April 22, 2023
Fully equipped labs with 75-member team set-up and made operational in <100 days
